Survey reveals patient groups’ views on pharma industry
March 10, 2016Research and Development, Sales and Marketing patientview
A new report, published by research and consultancy group PatientView, has revealed the attitude of more than 1,000 patient groups …
Seven quick facts about meldonium – and why it will get Sharapova banned
March 10, 2016Medical Communications, Research and Development 7 things, anti-doping, banned, maria sharapova, medlonum, reasons, susbtance
It’s made world headlines this week, but the drug meldonium would have been unknown to many before it emerged that …
Engineers create lab-grown heart and liver tissue for drug testing and discovery
March 10, 2016Manufacturing and Production, Research and Development 3D, angiochip, artificial heart, drug delivery, innovation, liver, vessels
Researchers at University of Toronto have developed “person-on-a-chip” technology which sees the growing of realistic human tissues outside the body. …
Genmab Darzalex success triggers second milestone payment
March 10, 2016Research and Development, Sales and Marketing Genmab, Janssen, daratumumab, darzalex, follicular lymphoma
Genmab says it has reached a $5 million milestone in its daratumumab collaboration with Janssen as a result of success …
Valeant ends controversial litigation with R&O Pharmacy
March 10, 2016Litigation, Philidor, Valeant, controversy, r&o pharmacy, scandal
Valeant has announced that, in conjunction with R&O Pharmacy, its has jointly requested that the Court dismiss the litigation between …
Tackling Chronic Kidney Disease – early action will aid prevention this World Kidney Day 2016
March 10, 2016Medical Communications, Research and Development
Today (10th March) marks World Kidney Day 2016. Now in its 11th year, it is the largest such event focused …
Sanofi appoints Novartis executive Dr Ameet Nathwani executive VP and CMO
March 10, 2016Medical Communications
Sanofi has announced the appointment of Dr Ameet Nathwani as a new member of its Executive Committee, and to the …
Rigel names Anne-Marie Duliege chief medical officer
March 9, 2016Medical Communications
Biotech firm Rigel Pharmaceuticals (Nasdaq: RIGL) named Anne-Marie Duliege its chief medical officer, replacing Elliott Grossbard, who is retiring.Dr Grossbard will remain …
Shire launches long-acting ADHD drug in UK
March 9, 2016Sales and Marketing ADHD, Shire
Shire has launched its long-acting ADHD drug Intuniv (guanfacine) in the UK, for children and adolescents aged 6-17. The treatment …
Pfizer enters $5 billion share buyback deal with Goldman Sachs
March 9, 2016Business Services, Research and Development Pfizer, Share buyback, Stock, markets
US drug major Pfizer (NYSE: PFE) on Wednesday said it has entered into an accelerated share repurchase agreement with Goldman, …
Pharma industry’s contribution to NHS medicines bill tops £1 billion
March 9, 2016Manufacturing and Production, Medical Communications, Research and Development ABPI, PPRS, goodwill, pharma industry
The pharmaceutical industry has now contributed over £1 billion to the Department of Health towards the cost of new medicines …
Late-stage Pfizer drug study shows significant reduction in haemophilia B bleeding
March 9, 2016Research and Development BeneFIX, Pfizer, haemophilia B
Pfizer on Wednesday said late-stage trials for its drug candidate to treat haemophilia B showed prophylactic use resulted in significant reduction …
TiGenix says additional data for stem cell product affirms safety profile
March 9, 2016Research and Development Crohn’s disease, TiGenix, crohn's disease, drug trial
Belgian biotech firm TiGenix said the results of a 52-week follow-up study of its trial drug for a stem-cell condition …
Merck chief executive Karl-Ludwig Kley to step down in April
March 9, 2016Medical Communications, Research and Development Denreon, Karl-Ludwig Kley, Merck, karl ludwig kley
It has been announced that Karl-Ludwig Kley, chief executive officer at Merck, will step down from his position at the …
French clinical trial tragedy “astonishing and unprecedented”, says report
March 9, 2016Medical Communications, Research and Development Bial, Biotrial, France, clinical trial, death, rennes, tragedy
A report into the clinical trial tragedy in France in January has called the event “astonishing and unprecedented” but did …
Ipsen and PeptiMimesis announce oncology research partnership
March 9, 2016Research and Development INSERM, PeptiMimesis, ipsen, peptides
Specialist pharma company Ipsen is partnering with French start-up PeptiMimesis to develop and market of novel therapeutic peptides in oncology. …
Crown Bioscience expands portfolio with PreClinOmics acquisition
March 9, 2016Manufacturing and Production, Research and Development cardiovascular, collaboration, crown bioscience, metabolic, preclinomics
Crown Bioscience has announced the acquisition of PreClinOmics, which will see the US-based drug discovery solutions company expand its cardiovascular …
MSD joins charity-industry partnership Dementia Consortium
March 9, 2016Medical Communications, Research and Development MSD, alzheimer's society, dementia, dementia consortium
The Dementia Consortium has welcomed MSD into the fold as a new partner in its global venture to accelerate drug …
AZ drug gets orphan status for rare inflammatory disease
March 9, 2016Research and Development AstraZeneca, MEDI-551, MedImmune, orphan drug
AstraZeneca’s biologics R&D arm MedImmune has been granted Orphan Drug Designation by the FDA for its investigational anti-CD19 monoclonal antibody, …
Genmab ends ofatumumab trials for autoimmune conditions; to focus on multiple sclerosis
March 9, 2016Research and Development Arzerra, GSK
Danish drug-company Genmab (Nasdaq Copenhagen: GEN) said it will discontinue the late-stage trials for Arzerra (ofatumumab) to develop a treatment for …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
